Mallinckrodt (MNK) Announces Enrollment of First Patient in Phase 1 Study of ExpressGraft C9T1 Skin Tissue
Tweet Send to a Friend
Mallinckrodt plc (NYSE: MNK) today confirmed enrollment of the first patient in the company's Phase 1 study assessing the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE